A new cancer vaccine based on Covid mRNA vaccine technology
which has yet to be clinically tested has already been declared “safe
and effective” by the British government.
Known as ‘LungVax’,
the new vaccine is being developed by the University of Oxford, the
Francis Crick Institute and University College London, and is expected
to be the first of a huge range of new cancer vaccinations available in
the near future.
Research scientists developing the ‘groundbreaking’ lung cancer
vaccine claim it will be effective in preventing up to 90 per cent of
cases by training the immune system to locate and attack early signs of
disease.
Lung cancer cells look different from normal cells due to having ‘red
flag’ proteins called neoantigens. The LungVax vaccine will carry a strand of DNA which trains the immune system to recognize these neoantigens on abnormal lung cells.
It will then instruct the immune system to destroy these cells and stop lung cancer.
Professor Tim Elliot, lead researcher at the University of Oxford, said: ‘Cancer
is a disease of our own bodies and it’s hard for the immune system to
distinguish between what’s normal and what’s cancer.
‘Getting the immune system to recognize and attack cancer is one of the biggest challenges in cancer research today.”
Elliot admitted the new vaccine is based on technology used to create the Covid vaccine.
‘This research could deliver an off-the-shelf vaccine based on
Oxford’s vaccine technology, which proved itself in the Covid pandemic.
Remarkably, given the disastrous health consequences for those
vaccinated with the experimental Covid vaccines, Eilliot praised the
mRNA roll out as a success.
‘If we can replicate the kind of success seen in trials during
the pandemic, we could save the lives of tens of thousands of people
every year in the UK alone.’
Researchers have been granted up to £1.7 million from Cancer Research UK and the CRIS Cancer Foundation.
The team will receive funding for the study over the next 2 years to
support lab research and initial manufacturing of 3,000 doses of the
vaccine at the Oxford Clinical BioManufacturing Facility.
If successful, the vaccine will move straight into a clinical trials,
involving those at biggest risk of disease, such as current and former
smokers who currently qualify for targeted lung health checks in some
parts of the UK.
Click this link for the original source of this article.
Author: Planet Today
This content is courtesy of, and owned and copyrighted by, https://www.planet-today.com and its author. This content is made available by use of the public RSS feed offered by the host site and is used for educational purposes only. If you are the author or represent the host site and would like this content removed now and in the future, please contact USSANews.com using the email address in the Contact page found in the website menu.